I am an Assistant Professor at Dana-Farber Cancer Institute (DFCI) specializing in clinical investigations of CLL. Until 2021, I served as PI of investigator-sponsored studies at the NIH, including two trials specifically designed for CLL patients with high-risk genomic features. These efforts provided the largest and longest follow-up experience available for TP53 aberrant CLL treated with ibrutinib and revealed BTK mutations leading to treatment resistance. My immediate research goal is to apply the skills and knowledge learned from the previous work to investigate mechanisms of drug resistance emerging after targeted combination therapy. I have established collaboration with other investigators and am prospectively collecting research samples from a phase 2 study of zanubrutinib and venetoclax (NCT05168930). I envision data from the study will establish genomic markers as a decision-making tool that informs the selection of treatment regimens and modification of treatment duration.